Occurrence of slipped capital femoral epiphysis in children undergoing gonadotropin-releasing hormone agonist therapy for the treatment of central precocious puberty

https://pubmed.ncbi.nlm.nih.gov/23859950/

Can GnRH-agonist treatment cause slipped capital femoral epiphysis?

https://pubmed.ncbi.nlm.nih.gov/11453522/

There are a few reports of side-effects of LHRHa treatment in childhood, the mechanisms of which remain little understood. Such effects can be local reactions: erythema, induration, wheal and sterile abscess formation, which can be possible causes of therapy failure. There are negative effects on growth velocity and final height requiring rhGH therapy or a suppressive treatment when bone age >13 years. Excessive weight gain can occur by various mechanisms: menopausal-like phenomena, or LHRHa influ-ence on hypothalamic and/or leptin-mediated control of body weight. Other possible adverse effects involve increased ovarian volume with possible POS development; however, there is no evidence correlating LHRHa, hyperandrogen-ism and POS. The latter appears related to CPP onset with pre-existing hyperandrogenism, al-though lengthier follow-up is necessary to confirm this. Bone density decreases during therapy, but final peak bone mass is in the normal range. Frequent transitory side-effects include headaches, hot flushes, depression and irregular menses.

https://www.degruyter.com/document/doi/10.1515/JPEM.2000.13.S1.795/html